



An Anthem Company

NEW YORK Provider Communications

Specialty pharmacy prior authorization update - Certain drugs for treatment of ocular conditions continue to require prior authorization

Published: May 1, 2021 - Products & Programs / Pharmacy

In the [March 2021 issue of Provider News](#), we advised we would no longer require prior authorization for the following drugs used to treat ocular conditions effective May 1, 2021. **Please be advised that prior authorization will continue to be required for these drugs.** We apologize for any inconvenience.

Drug	Code	Code description
*Avastin	C9257 J9035	intravitreal bevacizumab
*Mvasi	Q5107	bevacizumab-awwb
*Zirabev	Q5118	bevacizumab-bvzr

*Non-oncology use is managed by Empire's medical specialty drug review team.

1160-0521-PN-NY

URL: <https://providernews.empireblue.com/article/specialty-pharmacy-prior-authorization-update-certain-drugs-for-treatment-of-ocular-conditions-continue-to-require-prior-authorization-7>

Featured In:
May 2021 Newsletter

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.